CN106432229B - 一类用于治疗或预防高尿酸血症或痛风的化合物 - Google Patents

一类用于治疗或预防高尿酸血症或痛风的化合物 Download PDF

Info

Publication number
CN106432229B
CN106432229B CN201610810990.4A CN201610810990A CN106432229B CN 106432229 B CN106432229 B CN 106432229B CN 201610810990 A CN201610810990 A CN 201610810990A CN 106432229 B CN106432229 B CN 106432229B
Authority
CN
China
Prior art keywords
methanone
pyridin
ethylimidazo
hydroxyphenyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201610810990.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN106432229A (zh
Inventor
史东方
傅长金
承曦
朱江华
文杰
顾杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou New Element Pharmaceutical Co ltd
Original Assignee
Jiangsu New Medical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu New Medical Technology Co Ltd filed Critical Jiangsu New Medical Technology Co Ltd
Priority to TW105131659A priority Critical patent/TWI681772B/zh
Publication of CN106432229A publication Critical patent/CN106432229A/zh
Application granted granted Critical
Publication of CN106432229B publication Critical patent/CN106432229B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201610810990.4A 2015-09-10 2016-09-08 一类用于治疗或预防高尿酸血症或痛风的化合物 Active CN106432229B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW105131659A TWI681772B (zh) 2015-09-10 2016-09-30 用於治療或預防高尿酸血症或痛風的化合物及其用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510576110 2015-09-10
CN2015105761107 2015-09-10

Publications (2)

Publication Number Publication Date
CN106432229A CN106432229A (zh) 2017-02-22
CN106432229B true CN106432229B (zh) 2018-01-12

Family

ID=58164535

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610810990.4A Active CN106432229B (zh) 2015-09-10 2016-09-08 一类用于治疗或预防高尿酸血症或痛风的化合物

Country Status (27)

Country Link
US (1) US10399971B2 (https=)
EP (1) EP3348557B1 (https=)
JP (1) JP6635527B2 (https=)
KR (1) KR102109061B1 (https=)
CN (1) CN106432229B (https=)
AU (1) AU2016320073B2 (https=)
BR (1) BR112018004863B1 (https=)
CA (1) CA2998034C (https=)
CY (1) CY1123137T1 (https=)
DK (1) DK3348557T3 (https=)
EA (1) EA037280B1 (https=)
ES (1) ES2803223T3 (https=)
HR (1) HRP20201094T1 (https=)
HU (1) HUE051448T2 (https=)
IL (1) IL257960A (https=)
LT (1) LT3348557T (https=)
MX (1) MX375068B (https=)
MY (1) MY195675A (https=)
NZ (1) NZ741318A (https=)
PL (1) PL3348557T3 (https=)
PT (1) PT3348557T (https=)
RS (1) RS60697B1 (https=)
SG (1) SG11201802010QA (https=)
SI (1) SI3348557T1 (https=)
TW (1) TWI681772B (https=)
WO (1) WO2017041732A1 (https=)
ZA (1) ZA201802312B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018090921A1 (zh) * 2016-11-16 2018-05-24 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
CN108084186B (zh) * 2016-11-16 2021-06-25 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
EP3632904B1 (en) * 2017-05-26 2022-04-20 Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. Urat1 inhibitors for promoting uric acid excretion
CN114213331B (zh) * 2017-05-26 2024-06-21 江苏新元素医药科技有限公司 一类urat1抑制剂及其应用
CN112979661B (zh) * 2018-01-19 2022-05-17 苏州信诺维医药科技股份有限公司 杂环化合物、制备方法及其在医药上的应用
CN111410654B (zh) * 2019-01-19 2022-05-17 江苏新元素医药科技有限公司 3-溴-5-(2-乙基咪唑并[1,2-a]吡啶-3-羰基)-2-羟基苯甲腈的合成
CN111943957B (zh) * 2019-05-17 2023-01-06 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
WO2022169974A1 (en) 2021-02-05 2022-08-11 Nexys Therapeutics, Inc. Inhibitors of urat1 and pharmaceutical uses thereof
CN113717072A (zh) * 2021-09-28 2021-11-30 铜仁百朗制药有限公司 一种治疗便秘药物中间体的制备方法
CN116715633B (zh) * 2022-04-27 2025-08-12 杭州新元素药业股份有限公司 可用于降尿酸的化合物
WO2023221078A1 (en) * 2022-05-20 2023-11-23 Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. Solid forms of a compound for treating or preventing hyperuricemia or gout
TWI898321B (zh) * 2023-11-17 2025-09-21 大陸商杭州新元素藥業有限公司 用於治療或預防高尿酸血症或痛風的化合物的固體晶型
WO2025237171A1 (zh) * 2024-05-11 2025-11-20 广州市联瑞制药有限公司 嘧啶并五元氮杂环酚类化合物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4400387A (en) * 1979-07-06 1983-08-23 S. A. Labaz-Sanofi N.V. Indolizine derivatives and uses in therapeutics
FR2647451B1 (fr) * 1989-05-26 1994-08-05 Sanofi Sa Derives d'imidazo(1,2-a)pyridine, procede de preparation, compositions pharmaceutiques les contenant

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5325065B2 (ja) * 2009-09-30 2013-10-23 株式会社富士薬品 新規フェノール誘導体
US10005750B2 (en) * 2010-10-06 2018-06-26 J-Pharma Co., Ltd. Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
WO2014017643A1 (ja) * 2012-07-27 2014-01-30 佐藤製薬株式会社 ジフルオロメチレン化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4400387A (en) * 1979-07-06 1983-08-23 S. A. Labaz-Sanofi N.V. Indolizine derivatives and uses in therapeutics
FR2647451B1 (fr) * 1989-05-26 1994-08-05 Sanofi Sa Derives d'imidazo(1,2-a)pyridine, procede de preparation, compositions pharmaceutiques les contenant

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bicyclic imidazo derivatives, a new class of highly selective inhibitors for the human immunodeficiency virus type 1;Christiane Moog等;《Antiviral Research》;19941231;第24卷;275-288 *

Also Published As

Publication number Publication date
SI3348557T1 (sl) 2020-09-30
HRP20201094T1 (hr) 2020-10-30
ZA201802312B (en) 2024-11-27
CN106432229A (zh) 2017-02-22
RS60697B1 (sr) 2020-09-30
DK3348557T3 (da) 2020-07-20
AU2016320073A1 (en) 2018-04-26
CA2998034C (en) 2021-05-04
BR112018004863B1 (pt) 2023-04-18
JP6635527B2 (ja) 2020-01-29
SG11201802010QA (en) 2018-04-27
EA201890694A1 (ru) 2018-10-31
KR20180044426A (ko) 2018-05-02
MX2018003006A (es) 2018-08-09
US10399971B2 (en) 2019-09-03
HUE051448T2 (hu) 2021-03-01
MX375068B (es) 2025-03-06
TW201808284A (zh) 2018-03-16
CA2998034A1 (en) 2017-03-16
ES2803223T3 (es) 2021-01-25
TWI681772B (zh) 2020-01-11
US20180282321A1 (en) 2018-10-04
EP3348557A1 (en) 2018-07-18
KR102109061B1 (ko) 2020-05-11
IL257960A (en) 2018-05-31
AU2016320073B2 (en) 2019-05-09
EP3348557A4 (en) 2019-03-06
JP2018526417A (ja) 2018-09-13
EP3348557B1 (en) 2020-04-29
BR112018004863A2 (https=) 2018-10-02
PT3348557T (pt) 2020-08-03
CY1123137T1 (el) 2021-10-29
PL3348557T3 (pl) 2020-11-16
NZ741318A (en) 2019-03-29
LT3348557T (lt) 2020-08-10
WO2017041732A1 (zh) 2017-03-16
EA037280B1 (ru) 2021-03-03
MY195675A (en) 2023-02-03

Similar Documents

Publication Publication Date Title
CN106432229B (zh) 一类用于治疗或预防高尿酸血症或痛风的化合物
CN110167918A (zh) 新型苯基衍生物
CN111285829B (zh) 一类PPARγ/δ双重激动剂、其制备方法及其作为药物的用途
JP7071981B2 (ja) 疾患の治療のための二置換ピラゾール化合物
CN108084186A (zh) Urat1抑制剂及其应用
KR102420892B1 (ko) 요산 배출을 촉진시키는 urat1 억제제
CN107683282A (zh) 新型urat1抑制剂及其在医药上的应用
CN106065010A (zh) 用于治疗或预防高尿酸血症或痛风的化合物
CN107759588A (zh) 一类苯基‑(吡唑并[1,5‑a]吡啶‑3‑基)甲酮衍生物
EP3735404B1 (en) Ask1 inhibitor compounds and uses thereof
KR101870968B1 (ko) Ppar, fxr 및 ampk 활성화 효능을 갖는 신규 티오펜 화합물 또는 이의 약제학적으로 허용 가능한 염 및 이의 의학적 용도
CN115124531A (zh) 一类4-氮杂色胺酮芳香硫醚衍生物、制备方法及应用
JP2022062193A (ja) 不飽和脂肪族オレフィン性結合を含有するチエノピリジン誘導体、その調製方法および使用
CN114195776A (zh) 新型fxr小分子激动剂制备及其用途
EP4245365B1 (en) A fxr small molecule agonist, the preparation and use thereof
CN111793066B (zh) 苯并五元杂环磺酰胺类化合物、其制备方法、药物组合物及应用
CN110423213B (zh) 一种阿普斯特衍生物及其制备方法与应用
TWI828783B (zh) 聯芳基衍生物及其用途
CN110240537B (zh) 一种茚氧乙酸类化合物及其制备方法和用途
CN118894802A (zh) 一种选择性THRβ激动剂化合物及用途
CN104650031A (zh) 芳香多环羧酸衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address

Address after: Room 306, Building 21, Hexiang Technology Center, Xiasha Street, Qiantang District, Hangzhou City, Zhejiang Province 311222

Patentee after: Hangzhou New Element Pharmaceutical Co.,Ltd.

Country or region after: China

Address before: Building 18, No. 99 Dingmao Jing 15th Road, New District, Zhenjiang City, Jiangsu Province

Patentee before: JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL Co.,Ltd.

Country or region before: China

CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: 310018 Zhejiang Province, Hangzhou City, Qiantang District, Xiaoshan Street, Yinhai Science and Technology Innovation Center, Building 10, Room 201-1

Patentee after: Hangzhou New Element Pharmaceutical Co.,Ltd.

Country or region after: China

Address before: Room 306, Building 21, Hexiang Technology Center, Xiasha Street, Qiantang District, Hangzhou City, Zhejiang Province

Patentee before: Hangzhou New Element Pharmaceutical Co.,Ltd.

Country or region before: China

CP03 Change of name, title or address